|
|
Line 43: |
Line 43: |
|
| |
|
|
| |
|
| ==Table==
| | {{Family tree/start}} |
| | | {{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | A01= <div style="float: left; text-align: left; width: 18em; padding:1em;">'''Identify cardinal signs and symptoms that increase the pretest probability of pericarditis'''<br> |
| {| style="background: #FFFFFF;" | | ❑ [[Tachycardia]] <br> ❑ [[Hypotension]]<br>❑ [[Loss of consciousness]]<br>❑ Severe [[dyspnea]]<br> |
| | valign=top | | | </div>}} |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| | {{familytree | | | | | | | | | | | | | |!| | | | | | | }} |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of focal atrial tachycardia}}
| | {{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | A01= <div style="float: left; text-align: left; width: 18em; padding:1em;">'''Determine if the patient is unstable'''<br></div>}} |
| |- | | {{familytree | | | | | | | | | | |,|-|-|^|-|-|.| | | | |}} |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Acute treatment''''' | | {{familytree | | | | | | | | | | B01 | | | | B02 | | | | B01=<div style=" background: #F60A0A"> {{fontcolor|#F8F8FF|'''Unstable patient'''}}</div> | B02= '''Stable patient'''|border=0}} |
| |- | | {{familytree | | | | | | | | | | |!| | | | | |!| | | | }} |
| | style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Conversion in hemodynamically unstable patient'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left|▸ '''''[[DC cardioversion]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]]) | | {{familytree | | | | | | | | | | A01 | | | | |!| | | | | A01= <div style="float: left; text-align: left; width: 18em; padding:1em;">'''Suspect cardiac tamponade'''<br></div>}} |
| |- | | {{familytree | | | | | | | | | | |!| | | | | |!| | | | }} |
| | style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Conversion in hemodynamically stable patient'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Adenosine]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR> ▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blocker]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Procainamide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]]) | | {{familytree | | | | | | | | | | C01 | | | | C02 | | | | C01=<div style=" background: #F60A0A; text-align: left; width: 22em"> {{fontcolor|#F8F8FF|❑ Look for Beck's triad <br> ❑ Pulsus paradoxus <br> ❑ Muffled heart sounds<br> ❑ Hypotension}}</div> |border=red|C02=Continue with complete diagnostic approach}} |
| |- | | {{familytree | | | | | | | | | | |!| | | | | | | | | | }} |
| | style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Rate control'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blocker]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Digoxin]]''''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]]) | | {{familytree | | | | | | | | | | E01 | | | | | | | | | E01=<div style=" background: #F60A0A; text-align: left"> {{fontcolor|#F8F8FF| ❑ Assess airway, breathing, and circulation ([[ABC (medical)|<span style="color:white;">ABC</span>]]) <br> ❑ Administer [[oxygen|<span style="color:white;"> oxygen </span>]] if necessary }} </div> | C02=<div style="float: left; text-align: left; width: 15em; padding:1em;"> '''[[Aortic stenosis resident survival guide#Complete Diagnostic Approach to Aortic Stenosis|Continue with the diagnostic approach]]''' }}</div> | border=0}} |
| |- | | {{familytree | | | | | | | | | | |!| | | | | | | | | | }} |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Prophylactic therapy''''' | | {{familytree | | | | | | | | | | F01 | | | | | | | | | F01=<div style=" background: #F60A0A; text-align: left; width: 22em"> {{fontcolor|#F8F8FF| ❑ Treat the cardiac tamponade <br> |
| |- | | :: ❑ Resuscitate the patient<br> |
| | style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left| '''''Recurrent symptomatic [[atrial tachycardia]]'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR> ▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Disopyramide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]]) | | :: ❑ Bedside echo<br> |
| |- | | :: ❑ Urgent pericardiocentesis<br> |
| | style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left| '''''Asymptomatic or symptomatic incessent [[atrial tachycardia]]'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left |▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]]) | | :: ❑ Expert consultation |
| |-
| | }}</div> |border=red}} |
| |style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left| '''''Asymptomatic and non-sustained [[atrial tachycardia]]'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left |▸ '''''No therapy''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR> | | {{Family tree/end}} |
| ▸ '''''[[Catheter ablation]] ''''' ([[ACC AHA guidelines classification scheme|Class III, level of evidence C]])
| |
| |-
| |
| |}
| |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of focal and nonparoxysmal junctional tachycardia}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''[[Focal junctional tachycardia]]'''''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Non paroxysmal junctional tachycardia'''''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Reverse [[digitalis toxicity]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''AND''<BR>▸ '''''Correct [[hypokalemia]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''AND''<BR>▸ '''''Treat [[myocardial ischemia]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Calcium channel blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
| |
| |}
| |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of recurrent AVNRT}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''[[AVNRT]] with hemodynamic intolerance'''''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
| |
| |-
| |
| |style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Recurrent symptomatic [[AVNRT]]'''''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Digoxin]]''''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])
| |
| |-
| |
| |style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Recurrent [[AVNRT]] unresponsive to [[beta blockers]] and [[calcium channel blockers]],<br> patient not desiring [[radiofrequency ablation]]'' '''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]])<BR>''OR''<BR> ▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])
| |
| |-
| |
| |style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Single episode of [[AVNRT]] or infrequent [[AVNRT]]<br> in patients desiring complete control of arrhythmia'' '''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
| |
| |-
| |
| | |
| |style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Documented [[PSVT]] with only dual AV nodal pathways OR<br> single echo beats documented during electrophysiological study AND<br> no other cause of arrhythmia identified'' '''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
| |
| |-
| |
| |style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Infrequent, well tolerated [[AVNRT]]'' '''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''No therapy''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Vagal maneuvers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''Pill in the pocket''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
| |
| |-
| |
| |}
| |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of inappropriate sinus tachycardia}}
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
| |
| |-
| |
| |}
| |